During the last session, Ocular Therapeutix Inc (NASDAQ:OCUL)’s traded shares were 1.85 million, with the beta value of the company hitting 1.51. At the end of the trading day, the stock’s price was $7.67, reflecting an intraday gain of 1.86% or $0.14. The 52-week high for the OCUL share is $11.77, that puts it down -53.46 from that peak though still a striking 47.07% gain since the share price plummeted to a 52-week low of $4.06. The company’s market capitalization is $1.22B, and the average intraday trading volume over the past 10 days was 1.6 million shares, and the average trade volume was 1.20 million shares over the past three months.
Ocular Therapeutix Inc (OCUL) received a consensus recommendation of Buy from analysts. That translates to a mean rating of 1.08. OCUL has a Sell rating from 0 analyst(s) out of 3 analysts who have looked at this stock. 0 analyst(s) recommend to Hold the stock while 0 suggest Overweight, and 3 recommend a Buy rating for it. 0 analyst(s) has rated the stock Underweight. Company’s earnings per share (EPS) for the current quarter are expected to be -0.28.
Ocular Therapeutix Inc (NASDAQ:OCUL) trade information
Ocular Therapeutix Inc (OCUL) registered a 1.86% upside in the last session and has traded in the red over the past 5 sessions. The stock spiked 1.86% in intraday trading to $7.67, hitting a weekly high. The stock’s 5-day price performance is -0.39%, and it has moved by 13.29% in 30 days. Based on these gigs, the overall price performance for the year is -19.18%. The short interest in Ocular Therapeutix Inc (NASDAQ:OCUL) is 12.83 million shares and it means that shorts have 8.44 day(s) to cover.
The consensus price target of analysts on Wall Street is $19, which implies an increase of 59.63% to the stock’s current value. The extremes of the forecast give a target low and a target high price of $19 and $19 respectively. As a result, OCUL is trading at a discount of -147.72% off the target high and -147.72% off the low.
Ocular Therapeutix Inc (OCUL) estimates and forecasts
In the rating firms’ projections, revenue will increase 11.43% compared to the previous financial year.
As companies strive to predict their financial trajectories, we turn our attention to the forthcoming financial quarter. Here are the insights gathered from industry analysts. Revenue for the current quarter is expected to be 17.02M as predicted by 10 analyst(s). Meanwhile, a consensus of 10 analyst(s) estimates revenue growth to 17.7M by the end of current fiscal year. As per earnings report from last fiscal year’s results, sales for the corresponding quarters totaled 14.77M and 16.44M respectively. In this case, analysts expect current quarter sales to grow by 15.18% and then jump by 7.63% in the coming quarter.
An analysis of the company’s performance over the past 5 years shows that the company’s earnings grew an estimated 8.51%. While earnings are projected to return 0.73% in 2025, the next five years will return 4.84% per annum.
OCUL Dividends
Ocular Therapeutix Inc is due to release its next quarterly earnings on 2025-Mar-02. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.
Ocular Therapeutix Inc (NASDAQ:OCUL)’s Major holders
Ocular Therapeutix Inc insiders own 1.01% of total outstanding shares while institutional holders control 85.07%, with the float percentage being 85.93%. SUMMER ROAD LLC is the largest shareholder of the company, while 237.0 institutions own stock in it. As of 2024-06-30, the company held over 14.89 million shares (or 8.9767% of all shares), a total value of $101.82 million in shares.
The next largest institutional holding, with 12.76 million shares, is of VR ADVISER, LLC’s that is approximately 7.6964% of outstanding shares. At the market price on 2024-06-30, these shares were valued at $87.3 million.
